ASTH Astrana Health, Inc.

NEUTRAL Impact: 3/10 8-K
Horizon months Filed Jun 10, 2026 Processed 2d 18h ago SEC 0001104659-26-072343
8-K context-dependent: Items 5.02

Price Chart

Loading chart...

Executive Summary

Astrana Health filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment and restatement of the 2024 Equity Incentive Plan, increasing the share reserve by 1,000,000 shares to a total of 5,100,000 shares and extending the plan's term to March 2036. Nine directors were re-elected, and Ernst & Young was ratified as the independent auditor. This is a routine governance filing with no material financial impact.

Actionable Insight

Monitor for future equity grant volumes under the expanded plan. The incremental 1.8% potential dilution is modest and typical for growth-stage healthcare services companies. No immediate trading catalyst.

Key Facts

  • Shareholders approved an amendment to the 2024 Equity Incentive Plan, increasing the share reserve by 1,000,000 shares to 5,100,000 total shares.
  • The plan term was extended to March 24, 2036.
  • Nine directors were elected at the Annual Meeting held June 10, 2026.
  • Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal 2026.
  • Approximately 78.6% of outstanding shares were represented at the meeting, constituting a quorum.
  • CEO Brandon K. Sim signed the filing.

Financial Impact

Share count increase of 1,000,000 shares (approximately 1.8% of the 55,713,532 outstanding shares) authorized for equity grants; no immediate P&L impact.

dilutionshare count

Risk Factors

  • Future equity grants under the expanded plan could result in up to ~1.8% dilution to existing shareholders over time.
  • No other material risks identified from this routine governance filing.

Market Snapshot

Exchange
Nasdaq
Sector
Services-Management Consulting Services
Analyst Consensus
88% bullish (17 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-072343
Document: tm2614755d1_8k.htm0001104659-26-072343
Document: 0001104659-26-072343-index-headers.html0001104659-26-072343
Document: 0001104659-26-072343-index.html0001104659-26-072343
Document: 0001104659-26-072343.txt0001104659-26-072343
2 reports for ASTH
Performance horizon
Filters
Rows
Reports for ASTH — sortable, filterable
Type Now
Jun 10, 2026
2d ago
8-K
NEUTRAL ★ 3/10
$38.76 awaiting T+20awaiting T+20$38.62 (−0.36%)
Apr 17, 2026
8w ago
DEFA14A
NEUTRAL ★ 2/10
$31.50 $39.16▲ +24.32%▲ +18.95%$38.62 (+22.60%)
Showing 2 of 2

US Market Status

Market Closed — Opens Mon (47h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access